2A Peptide Antibody (3H4) [mFluor Violet 610 SE]

2A Peptide Antibody (3H4) [mFluor Violet 610 SE] [NBP2-59627MFV610] - Vial of mFluor Violet 610 conjugated antibody. mFluor Violet 610 is optimally excited at 421 nm by the Violet laser (405 nm) and has an emission maximum of 613 nm.

• Reactivity: All-NA
• Applications: WB, ICC/IF, IP
• Clone: 3H4
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: mFluor Violet 610 SE

2A Peptide Antibody (3H4) [mFluor Violet 610 SE] Summary

• Additional Information: Non-recombinant Monoclonal Antibody
• Immunogen: This 2A Peptide Antibody (3H4) was developed against KLH-coupled synthetic peptide corresponding to 2A peptide of Thosea asigna virus (CGDVEENPG)
• Specificity: This 2A Peptide Antibody (3H4) peptide antibody is specific for T2A and P2A tagged proteins. Specificity to F2A and E2A proteins has not been tested.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence
  • Immunoprecipitation
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined. Use in flow cytometry reported in PMID: 36356599 and customer review. Novus does not validate this product in flow cytometry and is unable to guarantee its performance.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein G purified

Notes

mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

Alternate Names for 2A Peptide Antibody (3H4) [mFluor Violet 610 SE]

• 2A cleavage peptide
• 2A Peptide Antibody
• 2A peptide tag
• 2A peptide
• 2A sequence
• 2A-like peptide
• antibody for 2A-containing recombinant proteins
• FMDV 2A-peptide antibody
• FMDV 2A-peptide
• MDV 2A-peptide
• P2A peptide
• P2A tagged proteins
• peptide 2A sequences
• self-cleaving 2A peptide
• T2A peptide
• T2A tagged proteins
• Thosea asigna virus 2A antibody
• Thosea asigna virus 2A

Background

Initially discovered from the foot-and-mouth disease virus (FMDV, a picornavirus), 2A peptide is a self-cleaving peptide 18-22 amino acids long with a conserved C-terminal motif Asp-Val/Ile-Glu-X-Asn-Pro-Gly-Pro. All picornaviruses have 2A peptides but they differ in size and function. The FMDV genome is a single open reading frame encoding a polyprotein and 2A denotes a specific cleavage region within the polyprotein. Co-translational cleavage of the FMDV polyprotein is not mediated by a proteolytic mechanism but rather by "ribosomal skipping" or "StopGO" at the 2A/2B junction. When synthesis terminates at a sense codon, the polypeptide is released before resuming translation at the next codon (1, 2).

Developed for genetic engineering, 2A cleavage has been shown to function in a wide range of eukaryotic cells, and in vivo (3). The 2A peptide is inserted between the coding sequences of at least two genes, enabling the simultaneous expression of multiple proteins from a single plasmid construct. Four variants of 2A peptides have been used in gene expression systems including FMDV 2A (F2A), equine rhinitis A virus 2A (E2A), porcine teschovirus-1 2A (P2A) or Thoseaasigna virus 2A (T2A). Compared to other multi-gene co-expression systems such as IRES, 2A peptides results in stoichiometric expression of different proteins. However, cleaving efficiency and protein expression using the different 2A peptides varies, requiring optimization of polycistronic constructs for experiments.

References

1. Liu Z, Chen O, Wall J, Zheng M, Zhou Y, Wang L, Vaseghi H, Qian L, Liu J. (2017). Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Scientific Reports. 7. 10.1038/s41598-017-02460-2.

2. Luke GA, Escuin H, Felipe PD, Ryan MD. (2009) 2A to the Fore - Research, Technology and Applications, Biotechnology and Genetic Engineering Reviews. 26(1): 223-260.

3. Markus BM, Bell GW, Lorenzi HA, Lourido S. (2019) Optimizing Systems for Cas9 Expression in Toxoplasma gondii. mSphere. 4(3): e00386-19.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.